Survodutide dosing is set by the Phase 2 and ongoing Phase 3 protocols from Boehringer Ingelheim and Zealand Pharma. The drug is a GLP-1 plus glucagon dual agonist administered as a once-weekly subcutaneous injection. The Phase 2 obesity trial (le Roux et al. 2024 Lancet) used a titration from 0.3 mg up to a maximum of 4.8 mg over 14 to 16 weeks, and the Phase 3 SYNCHRONIZE program is following a similar pattern.<\/p>\n
The titration is designed for GI tolerability. The GLP-1 component of survodutide drives potent gastric emptying delay and nausea at high doses, and starting at therapeutic levels would cause unacceptable symptoms in most patients. Gradual escalation gives the gut and brain time to adapt while still reaching effective doses within 4 months.<\/p>\n
This article walks through the titration schedule, what to expect during each phase, and how dose adjustments work for patients with intolerance or insufficient response. TrimRx provides personalized treatment plans for currently approved GLP-1 medications while survodutide moves through clinical development.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
The Phase 2 obesity trial started all participants at 0.3 mg subcutaneous once weekly.<\/strong> This is well below therapeutic levels and is chosen to introduce the body to GLP-1 plus glucagon agonism gradually.<\/p>\n Quick Answer: Phase 2 obesity titration started at 0.3 mg weekly and escalated through 0.9, 1.8, 2.7, 3.6, and 4.8 mg with 2 to 4 weeks at each dose<\/p>\n Some Phase 2 protocols used 0.6 mg as a starting dose for participants with prior GLP-1 exposure who had demonstrated tolerability. Most participants started at 0.3 mg regardless of prior treatment history.<\/p>\n The starting dose is held for 2 to 4 weeks before the first escalation. The variable duration reflects how patients tolerate the initial exposure. If GI symptoms are minimal at 2 weeks, escalation can proceed. If nausea persists, holding for an additional 2 weeks is reasonable.<\/p>\n The standard Phase 2 titration moved through these doses: 0.3 mg for weeks 1 to 4, then 0.9 mg for weeks 5 to 8, then 1.8 mg for weeks 9 to 12, then 2.7 mg for weeks 13 to 14, then 3.6 mg for weeks 15 to 16, then 4.8 mg from week 17 onward.<\/strong><\/p>\n Each step roughly doubles the dose at the lower end and increases by smaller increments at the higher end. The doubling pattern at low doses reflects the wide therapeutic window early in titration, while the smaller late steps prevent overshooting tolerability.<\/p>\n Faster titration is possible for tolerant patients. Some Phase 3 protocols offer a shorter 12-week titration for participants with no GI symptoms at 0.3 and 0.9 mg.<\/p>\n Weeks 1 to 4 at 0.3 mg.<\/strong> Most patients notice modest appetite reduction starting around day 4 to 7 after the first injection. Weight loss in this period is typically 1 to 4 pounds, mostly from reduced food intake.<\/p>\n GI symptoms are usually mild at 0.3 mg. About 25 percent of Phase 2 participants reported transient nausea in the first week. Symptoms typically resolved within 7 to 10 days as the body adapted.<\/p>\n Glucose effects are minimal at this dose. Patients with diabetes should monitor blood sugar but rarely need medication adjustments at 0.3 mg.<\/p>\n The 1.8 mg dose is the threshold where therapeutic effects become more pronounced.<\/strong> Weight loss rate accelerates, typically running 1 to 2 pounds per week during weeks 9 to 12 at 1.8 mg.<\/p>\n GI symptoms can flare with the escalation to 1.8 mg, especially in the first injection at the new dose. Pre-medicating with ondansetron 30 minutes before injection is reasonable for patients with prior GI sensitivity.<\/p>\n Glucose effects become more meaningful. Patients with type 2 diabetes may see A1C reductions accumulating. Adjustments to insulin or sulfonylureas may be needed starting at this dose level.<\/p>\n The 2.7 mg through 4.8 mg range is where Phase 2 obesity results were primarily generated.<\/strong> Mean weight loss at the highest dose was 14.9 percent at week 46 from baseline.<\/p>\n The MASH Phase 2 program tested up to 6.0 mg, with NASH resolution rates reaching 83 percent at the high dose. The 6.0 mg dose has not been extensively tested for obesity outside MASH-related trials.<\/p>\n Patients reaching 4.8 mg may experience plateau in weight loss after 8 to 12 weeks at the target dose. This is normal. The plateau reflects the body’s new metabolic equilibrium, and continued treatment maintains weight loss without necessarily driving further reductions.<\/p>\n If GI symptoms at a new dose are severe or unmanageable, dropping back to the previous tolerated dose for 2 to 4 weeks is the standard approach.<\/strong> The Phase 2 protocols allowed two dose reductions during the trial without protocol violation.<\/p>\n Some patients tolerate intermediate doses well and don’t need to reach the maximum 4.8 mg. The dose that produces good appetite control and weight loss with acceptable side effects is the right dose for that patient, regardless of whether it matches the trial maximum.<\/p>\n Dose holiday during severe symptoms (one week off, then resume at the previous dose) is another option for problematic GI flares.<\/p>\n Key Takeaway: Most patients reach target dose between week 14 and week 18, depending on dose escalation pace<\/p>\n If less than 3 days late, take the missed dose and continue the regular schedule.<\/strong> If 4 to 5 days late, skip the missed dose, wait at least 3 days, then resume the regular weekly schedule. If more than 5 days late, restart at the previous dose level for 1 to 2 weeks before resuming the original schedule.<\/p>\n The 7-day half-life means survodutide levels drop noticeably between weekly injections. A missed dose can lead to appetite rebound and GI symptom recurrence when the next dose is taken at full level.<\/p>\n For prolonged interruptions (more than 2 weeks), restart from a lower dose with abbreviated titration. Specific protocols depend on the duration of interruption.<\/p>\n Refrigerate at 36 to 46 degrees Fahrenheit.<\/strong> The drug can be stored at room temperature up to 86 degrees Fahrenheit for limited periods, expected to be 28 days based on standard GLP-1 stability data.<\/p>\n Never freeze. Frozen survodutide must be discarded regardless of appearance after thaw.<\/p>\n Protect from light. Original packaging blocks light effectively.<\/p>\n Phase 2 trials enrolled adults up to age 75 with no upper limit specified for Phase 3.<\/strong> Older adults typically tolerate slower titration with longer holds at lower doses.<\/p>\n Sarcopenia risk is a consideration with rapid weight loss in older adults. Protein intake of 1.2 to 1.6 grams per kilogram body weight daily and resistance training twice weekly are recommended.<\/p>\n Starting at 0.3 mg with 4-week holds at each step is a reasonable conservative approach for adults over 65.<\/p>\n Mild to moderate renal impairment does not require dose adjustment.<\/strong> Severe renal impairment (eGFR below 30) was excluded from Phase 2 and is a current uncertainty.<\/p>\n Liver disease eligibility actually favored survodutide in MASH-specific trials. Compensated liver disease with stable function is generally compatible with survodutide titration.<\/p>\n Severe hepatic impairment (Child-Pugh C) was excluded from most trials and remains an unstudied population.<\/p>\n Bottom line: Steady-state plasma levels are reached after about 5 weeks at any given dose, given the 7-day half-life<\/p>\n Most patients notice 1 to 4 pounds lost in the first 4 weeks at the starting dose. More pronounced weight loss begins at 1.8 mg and accumulates through titration.<\/p>\n Not recommended. Skipping steps risks severe GI symptoms that may force complete discontinuation.<\/p>\n A plateau after 12 to 16 weeks at the target dose is normal. The plateau reflects new equilibrium rather than treatment failure.<\/p>\n Likely yes, with standard titration. Prior GLP-1 tolerance doesn’t allow skipping titration but does suggest you’ll tolerate the schedule well.<\/p>\n Any consistent time works. Pick a day and time that fits your routine. Morning injections may produce noticeable appetite effects through that day’s meals.<\/p>\n Yes. Rotate among abdomen, thigh, and upper arm to prevent injection site reactions.<\/p>\n Survodutide is contraindicated in pregnancy. Discontinue immediately and notify your prescriber. Plan a 4 to 8 week washout before attempting conception when treatment is discontinued.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Survodutide dosing is set by the Phase 2 and ongoing Phase 3 protocols from Boehringer Ingelheim and Zealand Pharma.<\/p>\n","protected":false},"author":11,"featured_media":93367,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Survodutide Dosing Guide: Schedule, Titration & What to Expect Each Week","_yoast_wpseo_metadesc":"Survodutide dosing is set by the Phase 2 and ongoing Phase 3 protocols from Boehringer Ingelheim and Zealand Pharma.","_yoast_wpseo_focuskw":"survodutide dosing guide","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[6],"tags":[25,42,49],"class_list":["post-90679","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glp-1","tag-dosing","tag-results","tag-survodutide"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90679"}],"version-history":[{"count":3,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90679\/revisions"}],"predecessor-version":[{"id":92537,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90679\/revisions\/92537"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93367"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What Does the Titration Schedule Look Like?<\/h2>\n
What Should You Expect During the First Month?<\/h2>\n
What Changes When You Reach 1.8 Mg?<\/h2>\n
What About Doses 2.7 Mg and Above?<\/h2>\n
How Do You Handle Dose Adjustments for Intolerance?<\/h2>\n
What If You Miss a Dose?<\/h2>\n
How Do You Store Survodutide Between Injections?<\/h2>\n
Are There Special Considerations for Older Adults?<\/h2>\n
What About Patients with Kidney or Liver Disease?<\/h2>\n
FAQ<\/h2>\n
How Long Until I See Weight Loss?<\/h3>\n
Can I Skip Titration Steps?<\/h3>\n
What If My Weight Loss Plateaus?<\/h3>\n
Can I Take Survodutide If I Tolerated Semaglutide?<\/h3>\n
What Time of Day Should I Inject?<\/h3>\n
Can I Switch Injection Sites?<\/h3>\n
What If I Become Pregnant During Treatment?<\/h3>\n